5-Amino-1MQ

Metabolic & weight Research compound (not approved for human use)

NNMT inhibitor (small molecule) · also known as 5-Amino-1-methylquinolinium

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

5-Amino-1MQ is a small, cell-permeable molecule studied as a selective inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase). Research interest centers on metabolic effects such as fat oxidation, preservation of lean mass, and raising intracellular NAD+. It is reported both as an injectable (the vial figures here) and, more commonly, as oral capsules.

Commonly reported dosing (10 mg vial)

Reconstituted with 2 mL → 5 mg/mL.

Also sold in 50 mg vials.

Phase	Dose	Volume	U-100 units
Starting Days 1-2	2.5 mg	0.5 mL	50
Standard Day 3 onward	5 mg	1 mL	100

Frequency: Once or twice daily, subcutaneous or oral · Half-life: ~4-7 hours

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
2 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 5 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

NNMT consumes nicotinamide and methyl groups; when it is overexpressed in fat tissue it can lower NAD+ availability. By blocking NNMT, 5-Amino-1MQ is thought to spare nicotinamide for NAD+ synthesis and support downstream sirtuin (SIRT1) activity linked to mitochondrial function.

Researched for

Studied for reduced fat mass while sparing lean muscle in preclinical models.
Associated with higher NAD+ levels and SIRT1 pathway activity in research settings.
Evidence is preclinical (cell and rodent studies); controlled human data are lacking.

Notes

Research compound; human safety data are limited.
Oral capsules are the form most often reported; the vial and reconstitution figures here apply only to the injectable form, and oral amounts are not standardized.
In diet-induced obese mice, oral dosing gave low exposure (about 3.5% bioavailability) compared with subcutaneous dosing, so oral and injected amounts are not interchangeable.
A mild stinging sensation on injection has been reported.
Morning dosing is common; twice-daily splits track the short half-life.
Commonly reported reconstitution volumes are 2 mL for 10 mg vials and 4 mL for 50 mg vials.